Company news

Amneal Pharmaceuticals, Inc. news in 2021

Amneal Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

November 18, 2021

Amneal Reports Third Quarter 2021 Financial Results

November 2, 2021

Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company

November 1, 2021

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

October 26, 2021

Amneal to Report Third Quarter 2021 Results on November 3, 2021

October 5, 2021

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 24, 2021

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

August 22, 2021

Amneal Reports Second Quarter 2021 Financial Results

August 8, 2021

Amneal Receives Approval for Generic TobraDex®

July 18, 2021

Amneal to Report Second Quarter 2021 Results on August 9, 2021

July 14, 2021

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

June 16, 2021

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

June 6, 2021

Amneal Reports First Quarter 2021 Financial Results

May 6, 2021

Amneal to Report First Quarter 2021 Results on May 7, 2021

April 14, 2021

Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals

April 4, 2021

Amneal Reports Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021

Amneal Receives Approval for Generic Version of Ortho Evra®

February 25, 2021

Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021

February 3, 2021

Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals

January 11, 2021

Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA

January 7, 2021

Calls in 2021

Decks in 2021